Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 4, 2020
Previous Article Next Article

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Author affiliations

Abstract

Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor localities of tropical and sub-tropical areas with morbidity due to acute and chronic pathological manifestations of the disease. After a century since the first antimonial-based drugs were introduced to treat the disease, anti-schistosomiasis drug development is again at a bottleneck with only one drug, praziquantel, available for treatment purposes. This review focuses on promising chemotypes as potential starting points in a drug discovery effort to meet the urgent need for new schistosomicides.

Graphical abstract: Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Back to tab navigation

Article information


Submitted
24 Feb 2020
Accepted
22 Mar 2020
First published
06 Apr 2020

RSC Med. Chem., 2020,11, 455-490
Article type
Review Article

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

G. A. Dziwornu, H. D. Attram, S. Gachuhi and K. Chibale, RSC Med. Chem., 2020, 11, 455
DOI: 10.1039/D0MD00062K

Social activity

Search articles by author

Spotlight

Advertisements